Raltegravir

Active ingredient: Raltegravir Potassium

In short: Adult Patients Raltegravir tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients. Pediatric Patients Raltegravir tablets are indicated in combination with other antiretroviral agents for the treatme

Forms & strengthsFilm-coated Tablets 600 mg yellow, modified capsule shaped, biconvex, film-coated tablets debossed with "LU" on one side and "J04" on the other side.
LabelLupin Pharmaceuticals, Inc.
Label updatedOct 15, 2026

What is Raltegravir used for?

Adult Patients

Raltegravir tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients.

Pediatric Patients

Raltegravir tablets are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients weighing at least 40 kg.

Raltegravir dosage

Because the formulations have different pharmacokinetic profiles, do not substitute ISENTRESS chewable tablets or ISENTRESS for oral suspension for the raltegravir 400 mg film-coated tablet or the raltegravir 600 mg film-coated tablet.

Because the extent to which raltegravir tablets may be dialyzable is unknown, dosing before a dialysis session should be avoided .

Raltegravir film-coated tablets must be swallowed whole.

The recommended adult dosage of Raltegravir film-coated tablets are displayed in Table 1. Raltegravir tablets should be taken by mouth and may be taken with or without food .

Population | Recommended Dose

Treatment-naïve patients or patients who are virologically suppressed on an initial regimen of raltegravir tablets, 400 mg twice daily | 1,200 mg (2 x 600 mg) once daily or 400 mg twice daily

The recommended pediatric dosage of raltegravir tablets is displayed in Table 2. Raltegravir film-coated tablets should be taken by mouth and may be taken with or without food .

Recommended Pediatric Dosage and Formulation

Population/Weight | Film-Coated Tablets

,

400 mg | Film-Coated Tablets

,

600 mg

If at least 40 kg and either:

treatment-naïve or

virologically suppressed on an initial regimen of raltegravir tablets 400 mg twice daily | 400 mg twice daily | 1,200 mg (2 x 600 mg) once daily

No data are available in pre-term neonates. The use of raltegravir tablets is not recommended in preterm neonates.

How to take Raltegravir — instructions & advice from the label

Advise patients to read the FDA-approved patient labeling (Patient Information ).

Severe and Potentially

Life-threatening Rash

Inform patients that severe and potentially life-threatening rash has been reported. Advise patients to immediately contact their healthcare provider if they develop rash. Instruct patients to immediately stop taking raltegravir tablets, 600 mg and other suspect agents, and seek medical attention if they develop a rash associated with any of the following symptoms as it may be a sign of a more serious reaction such as Stevens-Johnson syndrome, toxic epidermal necrolysis or severe hypersensitivity: fever, generally ill feeling, extreme tiredness, muscle or joint aches, blisters, oral lesions, eye inflammation, facial swelling, swelling of the eyes, lips, mouth, breathing difficulty, and/or signs and symptoms of liver problems (e.g., yellowing of the skin or whites of the eyes, dark or tea colored urine, pale colored stools/bowel movements, nausea, vomiting, loss of appetite, or pain, aching or sensitivity on the right side below the ribs). …

Warnings & precautions

Do not take this medicine if: None

Severe, potentially life-threatening, and fatal skin reactions have been reported. These include cases of Stevens-Johnson syndrome and toxic epidermal necrolysis. Hypersensitivity reactions have also been reported and were characterized by rash, constitutional findings, and sometimes, organ dysfunction, including hepatic failure. Discontinue raltegravir tablets and other suspect agents immediately if signs or symptoms of severe skin reactions or hypersensitivity reactions develop (including, but not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, hepatitis, eosinophilia, angioedema). Clinical status including liver aminotransferases should be monitored and appropriate therapy initiated. Delay in stopping raltegravir tablets treatment or other suspect agents after the onset of severe rash may result in a life-threatening reaction.

Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including raltegravir tablets. During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jiroveci pneumonia, tuberculosis), which may necessitate further evaluation and treatment.

Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barr¡SR syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.

Raltegravir side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Treatment-Naive Adults

The safety of raltegravir tablets was evaluated in HIV-infected treatment-naive subjects in 2 Phase III studies: STARTMRK evaluated raltegravir tablets, 400 mg twice daily versus efavirenz, both in combination with emtricitabine (+) tenofovir disoproxil fumarate (TDF), and ONCEMRK evaluated raltegravir tablets, 1200 mg (2 x 600 mg) once daily versus raltegravir tablets, 400 mg twice daily, both in combination with emtricitabine (+) tenofovir disoproxil fumarate. Safety data from these two studies are presented side-by-side in Tables 6 and 7 to simplify presentation; direct comparisons across trials should not be made due to differing duration of follow-up and study design.

STARTMRK (Raltegravir Tablets 400 mg Twice Daily):

In STARTMRK, subjects received raltegravir tablets, 400 mg twice daily (N=281) or efavirenz (EFV) 600 mg at bedtime (N=282) both in combination with emtricitabine (+) tenofovir disoproxil fumarate, (N=282). …

Drug interactions

Raltegravir is not a substrate of cytochrome P450 (CYP) enzymes. Based on in vivo and in vitro studies, raltegravir is eliminated mainly by metabolism via a UGT1A1-mediated glucuronidation pathway. Coadministration of raltegravir tablets with drugs that inhibit UGT1A1 may increase plasma levels of raltegravir and coadministration of raltegravir tablets with drugs that induce UGT1A1, such as rifampin, may reduce plasma levels of raltegravir .

Selected drug interactions are presented in Table 11 . In some cases, recommendations differ for raltegravir tablets, 400 mg versus raltegravir tablets, 600 mg.

Concomitant

Drug

Class:

Drug

Name | Effect

on

Concentration

of

Raltegravir | Clinical Comment for Raltegravir Tablets,

400 mg | Clinical

Comment

for

Raltegravir Tablets,

600 mg

Metal-Containing

Antacids

Aluminum and/or magnesium-containing antacids | ↓ | Coadministration or staggered administration is not recommended.

Calcium carbonate antacid | ↓ | No dose adjustment | Co-administration is not recommended

Other

Agents

Rifampin | ↓ | The recommended dosage is 800 mg twice daily during coadministration with rifampin. There are no data to guide co- administration of raltegravir tablets with rifampin in patients below 18 years of age . | Coadministration is not recommended. …

About this medicine

Raltegravir tablets contain raltegravir potassium, a human immunodeficiency virus integrase strand transfer inhibitor. The chemical name for raltegravir potassium is N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(1-methyl-1-{[(5-methyl-1, 3, 4-oxadiazol-2-yl) carbonyl] amino} ethyl)-6-oxo-1,6- dihydro pyrimidine-4-carboxamide potassium.

The empirical formula is C20H20N6O5FK and the molecular weight is 482.51. The structural formula is:

Raltegravir potassium is a white to cream color powder. It is soluble in water, slightly soluble in methanol.

Each film coated tablet for oral administration contains 651.6 mg raltegravir potassium USP, equivalent to raltegravir 600 mg and the following inactive ingredients: croscarmellose sodium, magnesium stearate, microcrystalline cellulose, povidone K30 and tartaric acid. The film coating contains the following inactive ingredients: iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.

FDA approved dissolution test specifications differ from USP.

How it works: Raltegravir is an HIV-1 antiviral drug . …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID e9661839-bd2e-464f-a6df-6407b4a742b4. Read the full official label on DailyMed.

Related medicines

Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin